{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-027450","form_type":"8-K","ticker":"PRPO","cik":"0001043961","company_name":"Precipio, Inc.","filed_at":"2022-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.241218+00:00","generated_at":"2026-06-27T03:23:56.868236+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Precipio reports preliminary 2021 revenue of $8.9M, up 45% YoY; Q4 revenue $2.4M up 25%","bullets":["Preliminary unaudited 2021 revenue $8.9M, up $2.8M (45%) from 2020.","Q4-2021 revenue $2.4M, a 25% increase from $1.9M in Q4-2020.","HemeScreen product Q4-2021 revenue $0.4M vs <$0.1M full-year 2020; annualized contracts now >$1.6M.","2022 outlook projects meaningful growth in pathology and HemeScreen, aiming to materially reduce cash burn.","New panels (CLL, BCR-ABL) expected in 2022 to drive revenue per customer."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-027450","json":"https://secwatch.observer/filing/0001104659-22-027450.json","markdown":"https://secwatch.observer/filing/0001104659-22-027450.md","text":"https://secwatch.observer/filing/0001104659-22-027450.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1043961/000110465922027450/0001104659-22-027450-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1043961/000110465922027450/tm227800d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:23:56.868236+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}